Charles River Laboratories International, Inc. (CRL) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 37 analysts15.8% Below Target
CRL trades 15.8% below Wall Street's consensus target of $214.14.
Current Price$185.00
Average Target$214.14
Target
Current
Low$192.00
Median$219.00
High$220.00
Analyst Target Range
Forward P/E16.7x
(Fair)
PEG Ratio—
Implied Growth+394.1%
(High Growth)
Analyst Spread13.1%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes CRL achieves its forward estimates and maintains a stable P/E multiple of 16.7x. This scenario reflects the blended consensus of 37 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
CRL Price Target Analysis
Updated June 21, 2026As of June 21, 2026, Charles River Laboratories International, Inc. (CRL) has a Wall Street consensus price target of $214.14, based on estimates from 37 covering analysts. With the stock currently trading at $185.00, this represents a potential upside of +15.8%. The company has a market capitalization of $8.91B.
Analyst price targets range from a low of $192.00 to a high of $220.00, representing a 13% spread in expectations. The median target of $219.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 27 analysts rating the stock as a Buy or Strong Buy,10 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CRL trades at a trailing P/E of -63.6x and forward P/E of 16.7x. Analysts expect EPS to grow +394.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $89.50, with bear and bull scenarios of $56.39 and $117.93 respectively. Model confidence stands at 49/100, suggesting limited visibility into future performance.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+698.8%
Industry Consensus
Avg Forward P/E
27.2x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IQVIQVIA Holdings Inc. | $28.5B | $167.77 | $219.44 | +30.8% | Buy | 13.1x | 44 |
 MEDPMedpace Holdings, Inc. | $13.1B | $460.20 | $498.86 | +8.4% | Hold | 27.1x | 19 |
 ICLRICON Public Limited Company | $11.2B | $146.00 | $139.90 | -4.2% | Buy | 13.8x | 30 |
 PRAProAssurance Corporation | $1.3B | $24.65 | $18.33 | -25.6% | Hold | 20.1x | 11 |
 LBRTLiberty Energy Inc. | $4.4B | $27.18 | $34.71 | +27.7% | Buy | 101.9x | 19 |
 LHLabcorp Holdings Inc. | $21.1B | $255.82 | $311.33 | +21.7% | Buy | 14.2x | 35 |
 BCABBioAtla, Inc. | $5M | $3.65 | $250.00 | +6739.9% | Buy | — | 9 |
 NVCRNovoCure Limited | $1.6B | $14.28 | $33.00 | +131.1% | Buy | — | 15 |
 HALOHalozyme Therapeutics, Inc. | $8.1B | $68.55 | $88.25 | +28.7% | Buy | 8.5x | 27 |
 TMOThermo Fisher Scientific Inc. | $172.7B | $464.61 | $599.70 | +29.1% | Buy | 18.7x | 42 |
CRL — Frequently Asked Questions
Quick answers to the most common questions about buying CRL stock.
What is the CRL stock price target for 2026?
Charles River Laboratories International, Inc. (CRL) has a consensus 12-month price target of $214.14, implying 15.8% upside from $185. The 37 analysts covering CRL see moderate appreciation potential.
Is CRL a buy, sell, or hold?
CRL has a consensus rating of "Buy" based on 37 Wall Street analysts. The rating breakdown is predominantly bullish, with 27 Buy/Strong Buy ratings. The consensus 12-month price target of $214.14 implies 15.8% upside from current levels.
Is CRL stock overvalued or undervalued?
With a forward P/E of 16.676x, CRL trades at a relatively low valuation. The consensus target of $214.14 implies 15.8% appreciation, suggesting meaningful undervaluation.
How high can CRL stock go?
The most bullish Wall Street analyst has a price target of $220 for CRL, while the most conservative target is $192. The consensus of $214.14 represents the median expectation. Our quantitative valuation model projects a bull case target of $118 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover CRL stock?
CRL is heavily covered by Wall Street, with 37 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 26 have Buy ratings, 10 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the CRL stock forecast?
The 12-month CRL stock forecast based on 37 Wall Street analysts shows a consensus price target of $214.14, with estimates ranging from $192 (bear case) to $220 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $90, with bear/bull scenarios of $56/$118.
What is CRL's fair value based on fundamentals?
Our quantitative valuation model calculates CRL's fair value at $90 (base case), with a bear case of $56 and bull case of $118. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 49/100.
What is CRL's forward P/E ratio?
CRL trades at a forward P/E ratio of 16.7x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy CRL stock?
Wall Street analysts are optimistic on CRL, with a "Buy" consensus rating and $214.14 price target (15.8% upside). 27 of 37 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do CRL price targets vary so much?
CRL analyst price targets range from $192 to $220, a 13% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $214.14 consensus represents the middle ground. Our model's $56-$118 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare